Home » Posts tagged 'BLP1XA3FZA'
Tag Archives: BLP1XA3FZA
Venglustat, Ibiglustat


Venglustat, Ibiglustat
CAS 1401090-53-6
C20H24FN3O2S, 389.5 g/mol
CAS 1629063-78-0, Ibiglustat L-malate, Venglustat malate, C24H30FN3O7S, 523.6 g/mol
Infilbray, APPROVALS 2026, FDA 2026, Genz-682452, GZ/SAR402671, BLP1XA3FZA, SAR-402671, SAR 402671, Genz-682452-AA, BLP1XA3FZA, GZ402671, WHO 10063, Ibiglustat L-malate, Venglustat malate
[(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate
- [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate
- Carbamic acid, N-(1-(2-(4-fluorophenyl)-4-thiazolyl)-1-methylethyl)-, (3S)-1-azabicyclo(2.2.2)oct-3-yl ester
- (1S,3R,4S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
- (S)-quinuclidin-3-yl 2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-ylcarbamate
- (S)-Quinuclidin-3-yl(2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
- [(3S)-quinuclidin-3-yl] N-[1-[2-(4-fluorophenyl)thiazol-4-yl]-1-methyl-ethyl]carbamate
To treat the neurological symptoms of Type 3 Gaucher disease
Venglustat, sold under the brand name Infilbray, is a medication used for the treatment of Gaucher disease.[1] It is a glucosylceramide synthase inhibitor.[1] It is used as the salt venglustat malate.[1] It is given by mouth.[1]
The most common side effects of venglustat include gastrointestinal symptoms as well as adverse effects on mood.[2]
Venglustat was approved for medical use in the United States in November 2026.[2]
Medical uses
Venglustat indicated for the treatment of neurological manifestations of type 3 Gaucher disease in people weighing at least 15 kg (33 lb).[1]
Venglustat crosses the blood-brain barrier to reduce the accumulation of harmful substances in the body and brain.[2]
Type 3 Gaucher disease is a rare, inherited condition in which the body cannot properly break down fatty substances, called glucosphingolipids, due to a deficient or malfunctioning enzyme.[2]
Adverse effects
The most common side effects of venglustat include gastrointestinal symptoms as well as adverse effects on mood.[2]
Serious psychiatric risks, including suicidal ideation and behavior, have been reported.[2] Potential risks identified from animal studies include potential clouding of vision in younger people and adverse effects on fetal development when it is taken during pregnancy.[2]
History
The US Food and Drug Administration approved venglustat supported by data from a randomized, double-blind, multi-center clinical study enrolling 43 participants aged 12 years and older with type 3 Gaucher disease who had previously been treated with enzyme replacement therapy and had achieved systemic disease stabilization.[2] Participants received either venglustat orally once daily or intravenous enzyme replacement therapy every two weeks for 52 weeks.[2] Treatment effectiveness was evaluated using two assessments that capture the neurological symptoms central to daily life in participants with type 3 Gaucher disease, including those related to ataxia (loss of muscle control and coordination) and cognitive function.[2] At Week 52, participants treated with venglustat demonstrated improvement on a measure that combined both assessments compared to those taking enzyme replacement therapy for the treatment of non-neurologic manifestations of type 3 Gaucher disease.[2]
Society and culture
Legal status
Venglustat was approved for medical use in the United States in November 2026.[3]
The US Food and Drug Administration (FDA) granted the application for venglustat, breakthrough therapy, rare pediatric disease, fast track, orphan drug, and priority review designations.[2][3] The FDA granted the approval of Infilbray to Genzyme Corporation.[2]
Names
Venglustat is the international nonproprietary name.[4]
Venglustat is sold under the brand name Infilbray.[2][3]
SYN

SYN
WO2020/163244, 2020,
Organic Process Research and Development, 2015, vol. 19, V 5, PG 576 – 581
Journal of Medicinal Chemistry, 2023, vol. 66, V 2, PG1601 – 1615
PAT
WO2012129084 – GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012129084&_cid=P12-MWR8EI-85348-1

ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma



AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

……
References
- “Infilbray FDA label” (PDF). products.sanofi.us.
- “FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease” (Press release). FDA. 18 November 2026. Retrieved 19 November 2026.
This article incorporates text from this source, which is in the public domain. - “Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease”. Sanofi (Press release). 18 November 2026. Retrieved 19 November 2026.
- World Health Organization (2016). “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76”. WHO Drug Information. 30 (3). hdl:10665/331020.
Further reading
- Bhattiprolu M, Kappler M, Han TU, Henderson M, Serlin Y, Sidransky E (May 2026). “Pharmacotherapies for Gaucher disease: what’s new on the horizon?”. Expert Opinion on Pharmacotherapy. 27 (7): 585–597. doi:10.1080/14656566.2026.2667325. PMID 42153355.
External links
- “Venglustat ( Code – C152852 )”. EVS Explore.
- “Venglustat Malate ( Code – C171783 )”. EVS Explore.
- Clinical trial number NCT05222906 for “Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (LEAP2MONO)” at ClinicalTrials.gov
| Clinical data | |
|---|---|
| Trade names | Infilbray |
| AHFS/Drugs.com | Infilbray |
| License data | US DailyMed: Venglustat |
| Routes of administration | By mouth |
| Drug class | Glucosylceramide synthase inhibitor |
| ATC code | None |
| Legal status | |
| Legal status | US: ℞-only[1] |
| Identifiers | |
| IUPAC name | |
| CAS Number | 1401090-53-61629063-78-0 |
| PubChem CID | 6019924260199241 |
| IUPHAR/BPS | 11550 |
| DrugBank | DB14966 |
| ChemSpider | 34989426 |
| UNII | BLP1XA3FZA94855LQZ8D |
| KEGG | D11633D11634 |
| ChEBI | CHEBI:757083 |
| ChEMBL | ChEMBL4297611ChEMBL4594270 |
| PDB ligand | KYF (PDBe, RCSB PDB) |
| Chemical and physical data | |
| Formula | C20H24FN3O2S |
| Molar mass | 389.49 g·mol−1 |
| 3D model (JSmol) | Interactive imageInteractive image |
| SMILES | |
| InChI | |
PAT
- GLYCOSYLCERAMIDE SYNTHASE INHIBITORSPublication Number:BR-112013023774-B1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:EP-4559918-A2Priority Date:2011-03-18
- GLUCOSILCERAMIDE SINTASA INHIBITORS.Publication Number:MX-2013010710-APriority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:TW-I546301-BPriority Date:2011-03-18Grant Date:2016-08-21
- Glucosylceramide synthase inhibitorsPublication Number:KR-20140092239-APriority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2014255381-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2016207933-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:ES-2774293-T3Priority Date:2011-03-18Grant Date:2020-07-20
- Glucosylceramide synthase inhibitorsPublication Number:EP-3673906-B1Priority Date:2011-03-18Grant Date:2025-05-14
- GLYCOSYLCERAMIDE SYNTHASE INHIBITORSPublication Number:BR-122019017719-B1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:SG-193532-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2014255381-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2016207933-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:AU-2016244305-B2Priority Date:2011-03-18Grant Date:2018-05-24
- Glucosylceramide synthase inhibitorsPublication Number:AU-2016244305-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:AU-2012231275-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-2020048266-A1Priority Date:2011-03-18
- Glucosylceramide synthase inhibitorsPublication Number:US-9139580-B2Priority Date:2011-03-18Grant Date:2015-09-22
////////venglustat, ANAX LABS, Infilbray, APPROVALS 2026, FDA 2026, Genz-682452, GZ/SAR402671, BLP1XA3FZA, SAR-402671, SAR 402671, Genz-682452-AA, BLP1XA3FZA, GZ402671, WHO 10063, Ibiglustat L-malate, Venglustat malate
#venglustat, #ANAX LABS, #Infilbray, #APPROVALS 2026, #FDA 2026, #Genz-682452, #GZ/SAR402671, #BLP1XA3FZA, #SAR-402671, #SAR 402671, #Genz-682452-AA, #BLP1XA3FZA, #GZ402671, #WHO 10063, #Ibiglustat L-malate, #Venglustat malate
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....










